Nuwellis (NASDAQ:NUWE – Get Rating) and Hyperfine (NASDAQ:HYPR – Get Rating) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, risk, earnings, valuation and analyst recommendations.
Institutional & Insider Ownership
27.7% of Hyperfine shares are held by institutional investors. 0.9% of Nuwellis shares are held by insiders. Comparatively, 26.1% of Hyperfine shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Risk and Volatility
Nuwellis has a beta of 0.25, indicating that its share price is 75% less volatile than the S&P 500. Comparatively, Hyperfine has a beta of 0.29, indicating that its share price is 71% less volatile than the S&P 500.
Earnings & Valuation
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Nuwellis||$8.44 million||0.44||-$14.52 million||($88.76)||-0.03|
|Hyperfine||$6.81 million||15.45||-$73.16 million||($0.88)||-1.68|
Nuwellis has higher revenue and earnings than Hyperfine. Hyperfine is trading at a lower price-to-earnings ratio than Nuwellis, indicating that it is currently the more affordable of the two stocks.
This is a summary of recent recommendations for Nuwellis and Hyperfine, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Nuwellis presently has a consensus price target of $25.00, indicating a potential upside of 716.99%. Hyperfine has a consensus price target of $3.97, indicating a potential upside of 168.02%. Given Nuwellis’ higher probable upside, equities research analysts plainly believe Nuwellis is more favorable than Hyperfine.
This table compares Nuwellis and Hyperfine’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Hyperfine beats Nuwellis on 8 of the 12 factors compared between the two stocks.
Nuwellis, Inc. operates as a medical device company. It engages in the provision of products for the treatment of fluid overload. The firm’s products include Aquadex FlexFlow System, which provides an ultrafiltration for the removal of salt and water in patients with hypervolemia, or fluid overload. It operates through Cardiac and Coronary Disease Products segment. The company was founded by Crispin Marsh and William S. Peters in November 1999 and is headquartered in Eden Prairie, MN.
Hyperfine, Inc., a medical device company, provides magnetic resonance imaging (MRI) products. The company's products include Swoop Portable MR imaging system, which offers neuroimaging at the point of care, as well as informs the timely diagnosis and treatment of acute conditions in a wide range of clinical settings. Hyperfine, Inc. was incorporated in 2014 and is based in Guilford, Connecticut.
Receive News & Ratings for Nuwellis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuwellis and related companies with MarketBeat.com's FREE daily email newsletter.